Amitriptyline is an efficacious antidepressant drug .
It is , however , also associated with a number of side effects .
Degree of placebo response and severity of depression at baseline may moderate drug-placebo efficacy differences
BACKGROUND Amitriptyline is a tricyclic antidepressant that was synthesis ed in 1960 and introduced as early as 1961 in the USA , but is still regularly used .
It has also been frequently used as an active comparator in trials on newer antidepressants and can therefore be called a ' benchmark ' antidepressant .
However , its efficacy and safety compared to placebo in the treatment of major depression has not been assessed in a systematic review and meta- analysis .
OBJECTIVES To assess the effects of amitriptyline compared to placebo or no treatment for major depressive disorder in adults .
Demography, auxology and response to recombinant human growth hormone treatment in girls with Turner's syndrome in the Kabi Pharmacia International Growth Study
Demographic and auxological data were analysed from 818 girls with Turner 's syndrome treated with recombinant human growth hormone ( GH ) and entered into the Kabi Pharmacia International Growth Study . Size at birth was low and correlated with the heights of both parents . The median age at start of GH  treatment was 11.4 years and the parents had a median height SDS of ‐2.9 . Height SDS at the start of treatment correlated with parental heights . Height velocities conformed to Turner‐specific st and ards . The weight‐for‐height index increased sharply above 9 years of age . The frequency of spontaneous appearance of Tanner breast stage 2 was high ( 34.1 % of girls > 10 years of age ) . Bone age ( Greulich and Pyle ) data were described by the equation : bone age = 1.61 ( chronological age ) ‐0.04(chronological age)2 ‐ 3.61 . This equation was used to correct adult height predictions . The median initial dose of GH  was 0.8 IUkglweek and was maintained during the first 3 years of treatment . The median frequency of injections was six/week . Height velocity increased from 4.1 to 6.8 cm/year in the first year , and height velocity SDS for chronological age remained positive for 4 years . The height prediction corrected for bone age increased over the first 2 years only . Differences in demography and auxology were described according to karyotype and country of origin . A greater height velocity SDS was observed at higher GH doses and when ox and rolone was used concomitantly
Amitriptyline is an efficacious antidepressant drug .
It is , however , also associated with a number of side effects .
Degree of placebo response and severity of depression at baseline may moderate drug-placebo efficacy differences
BACKGROUND Amitriptyline is a tricyclic antidepressant that was synthesis ed in 1960 and introduced as early as 1961 in the USA , but is still regularly used .
It has also been frequently used as an active comparator in trials on newer antidepressants and can therefore be called a ' benchmark ' antidepressant .
However , its efficacy and safety compared to placebo in the treatment of major depression has not been assessed in a systematic review and meta- analysis .
OBJECTIVES To assess the effects of amitriptyline compared to placebo or no treatment for major depressive disorder in adults .